1. Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. N Engl J Med 2017;377:965-76. 
  2. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343-73. 
  3. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2017 update. 2017 (accessed 18 December 2017).
  4. National Asthma Council Australia. Australian Asthma Handbook. Melbourne: National Asthma Council Australia, 2017 (accessed 8 December 2017).
  5. Pharmaceutical Benefits Scheme. Tiotropium. 2017 (accessed 9 November 2017).
  6. Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev 2016:CD011721. 
  7. Boehringer Ingelheim Pty Limited. Spiriva Respimat (tiotropium bromide). Product Information. 2016 (accessed 5 December 2017).
  8. Pharmaceutical Benefits Scheme. Omalizumab. 2017 (accessed 9 November 2017).
  9. Pharmaceutical Benefits Scheme. Mepolizumab. 2017 (accessed 9 November 2017).
  10. Gibson PG, McDonald VM. Management of severe asthma: targeting the airways, comorbidities and risk factors. Intern Med J 2017;47:623-31.
  11. Novartis Pharmaceuticals Australia Pty Limited. Xolair Omalizumab (rch). Product information. 2017 (accessed 22 November 2017).
  12. GlaxoSmithKline Australia Pty L. Nucala (Mepolizumab). Product Information. 2016 (accessed 8 December 2017).
  13. Powell C, Milan SJ, Dwan K, et al. Mepolizumab versus placebo for asthma. Cochrane Database Syst Rev 2015:CD010834.
  14. Menzella F, Lusuardi M, Montanari G, et al. Clinical usefulness of mepolizumab in severe eosinophilic asthma. Ther Clin Risk Manag 2016;12:907-16. 
  15. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371:1189-97. 
  16. Centre of Excellence in Severe Asthma. Clinical Recommendations For The Use Of Omalizumab In Severe Asthma. 2017 (accessed 8 December 2017).
  17. Centre of Excellence in Severe Asthma. Clinical Recommendations For The Use Of Mepolizumab In Severe Asthma. 2017 (accessed 8 December 2017).